onlyuseInvestor Presentation
JP Morgan Virtual Healthcare Conference, January 2022
Precision Oncology See it. Treat it.
ersonal
Disclaimer
The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix onlyPharmaceuticals Limited ("Telix") in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy
or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.
This presentation may contain forward-looking statements which can be identified by the use of words such as "may", "should", "will", "expect", "anticipate", "believe",
"estimate", "intend", "scheduled" or "continue" or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks,
uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Telix, and its directors, officers, employees,
useThere can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Telix's product pipeline. Actual results from clinical trials may vary from those shown.
agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.
Telix's lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been approved by the Australian Therapeutic Goods Administration (TGA), and the U.S. Food and Drug Administration (FDA). Telix is also progressing marketing authorisation applications for Illuccix in the European Union and Canada. With the exception of Illuccix in the US and Australia and Scintimun®, none of Telix's products have received a marketing authorisation in any jurisdiction.
Full prescribing information for Illuccix can be found at http://illuccixhcp.com/s/illuccix-prescribing-information.pdf
Telix Pharmaceuticals Limited (ASX: TLX) | 2 |
ersonal |
An established global leader in radiopharmaceuticals
Extensive portfolio of diagnostic and | |||||
only | therapeutic assets with compelling | ||||
FDA | approval for TLX591-CDx (Illuccix®)2 | ||||
clinical data | |||||
12,150 patient doses in past 12 months1 | |||||
use | |||||
18 active clinical studies (8 indications)3 | |||||
ersonal | Leading supply chain and | ||||
distribution network | |||||
80 countries in the Telix distribution network | |||||
11 countries with a manufacturing footprint | |||||
1. | Clinical trial doses and magisterial / compassionate use of TLX591-CDx. 12 months from Q4 2020 | 3. Includes partnered investigator-led studies. |
2. United States Food and Drug Administration - ASX 20/12/21
Telix Pharmaceuticals Limited (ASX: TLX) | 3 |
Our strategy: See It. Treat it.
Personalised, precision medicine
Targeted radiation delivery | Systemically administered | |
onlyuse | Unique cancer cell | |
signature (target) | ||
ersonal |
Radioactive
isotope
Targeting agent
(a small molecule or antibody)
binds selectively to a
cancer cell
1. Positron emission tomography
2. Courtesy of Ammar Chaudhry MD, City of Hope, Duarte CA, USA.
Telix Pharmaceuticals Limited (ASX: TLX)
Imaging | PET1 scanner TLX591-CDx2 |
(Prostate cancer) |
68Ga, 89Zr (diagnostic isotopes)
Enables PET images of cancer
TherapyTLX591
(Prostate cancer)
177Lu, 131I, 225Ac
(therapeutic isotopes)
Enables precise radiation delivery to the cancer
4
Radiation has never been more important in cancer care
Underpinned by the shift from radiation "in a box" to radiation "in a shot"
The evolution from external-beam radiation to | From a 'box' | To a 'shot' | ||
only | ||||
systematically-deliveredand targeted radiation is | ||||
transforming the role of radiation in cancer care | ||||
• Synergy between imaging and therapy | ||||
• Broad cancer utility | ||||
use | ||||
• Potential to enhance existing drug | ||||
classes (androgens, taxanes etc.) | ||||
• A vitally important "primer" for | ||||
immuno-oncology | ||||
• A future cornerstone modality for | ||||
ersonal | gene/cell therapy conditioning | |||
Telix Pharmaceuticals Limited (ASX: TLX) | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Telix Pharmaceuticals Ltd. published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 22:57:01 UTC.